A8801007 A Phase I, Healthy Volunteer Qualification Of Ligand [C 11] PF 04621053 And Randomized Determination Of H3 Receptor Occupancy Of PF 03654746, Using PET

NCT00730990 Phase 1 COMPLETED

The primary purpose of this study is to assess central receptor occupancy of PF 03654746 at the H3 receptor after a single oral dose of PF 03654746.

Details

Lead sponsor	Pfizer
Phase	Phase 1
Status	COMPLETED
Enrolment	10
Start date	2008-05
Completion	2008-11

Conditions

• Healthy

Interventions

• Positron Emission tomography
• PET Scan with PF-03654746
• PET Scan with PF-03654746
• PET Scan with PF-03654746

Primary outcomes

• Overall H3 Receptor Occupancy of PF 03654746. — 48 hours

Countries

United States